This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01256/identifier/drugbank/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01256/identifier/national-drug-code-directory/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://www.rxlist.com/cgi/generic/
n16http://linked.opendata.cz/resource/drugbank/patent/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01256/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01256/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01256
rdf:type
n3:Drug
n3:description
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. It is marketed as an ointment under the name brand Altabax.
n3:dosage
n15:271B5FEB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# CenterWatch "Link":http://www.centerwatch.com/patient/drugs/dru946.html # Jones RN, Fritsche TR, Sader HS, Ross JE: Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16801451 # Yang LP, Keam SJ: Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68(6):855-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18416589 # Novak R, Shlaes DM: The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. 2010 Feb;11(2):182-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20112168 # Jacobs MR: Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. 2007 Dec;2:591-600. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18041900 # Parish LC, Parish JL: Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc). 2008 Feb;44(2):91-102. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18389088 # Retapamulin for impetigo and other infections. Drug Ther Bull. 2008 Oct;46(10):76-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18832258 # Nagabushan H: Retapamulin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2010 Jan-Feb;76(1):77-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20061745 # Shawar R, Scangarella-Oman N, Dalessandro M, Breton J, Twynholm M, Li G, Garges H: Topical retapamulin in the management of infected traumatic skin lesions. Ther Clin Risk Manag. 2009 Feb;5(1):41-9. Epub 2009 Mar 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436611
n3:group
approved
n3:indication
For use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm<sup>2</sup> in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
owl:sameAs
n11:DB01256 n17:DB01256
dcterms:title
Retapamulin
adms:identifier
n6:DB01256 n7:0007-5180-05 n18:PA164749341 n19:Retapamulin
n3:mechanismOfAction
Retapamulin is a bacterial protein synthesis inhibitor belonging to a class of compounds called pleuromutilins. These compounds inhibit the initiation of protein synthesis by binding to a specific site on the 50S subunit of bacterial ribosome (domain V of 23S rRNA). This binding site involves ribosomal protein L3 and is in the region of the ribosomal P site and peptidyl transferase center. By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, block P-site interactions, and prevent the normal formation of active 50S ribosomal subunits.
n3:packager
n20:271B5FE7-363D-11E5-9242-09173F13E4C5 n20:271B5FE8-363D-11E5-9242-09173F13E4C5 n20:271B5FE9-363D-11E5-9242-09173F13E4C5
n3:patent
n16:RE39128 n16:2307551
n3:proteinBinding
Retapamulin is approximately 94% bound to human plasma proteins, and the protein binding is independent of concentration.
n3:synthesisReference
Eli Lancry, Lilach Hedvati, Greta Sterimbaum, Ariel Mittelman, Tali Katav, "Amorphous retapamulin and processes for preparation thereof." U.S. Patent US20090234125, issued September 17, 2009.
n12:hasConcept
n13:M0496256
foaf:page
n9:altabax.htm n22:retapamulin-ointment.html
n3:IUPAC-Name
n4:271B5FF0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5FF6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5FF5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5FF2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5FF3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5FF4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5FEE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5FEC-363D-11E5-9242-09173F13E4C5 n4:271B5FEF-363D-11E5-9242-09173F13E4C5 n4:271B6006-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5FED-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:D06AX13
n3:H-Bond-Acceptor-Count
n4:271B5FFC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5FFD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5FF7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5FF8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5FFA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5FF9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5FFB-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Bacteria
n3:casRegistryNumber
224452-66-8
n3:category
n3:containedIn
n21:271B5FEA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6002-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6004-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6005-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6001-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6000-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6003-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5FF1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5FFE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5FFF-363D-11E5-9242-09173F13E4C5